What Is Tesamorelin?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) — the hypothalamic peptide that drives pulsatile growth hormone (GH) secretion from anterior pituitary somatotroph cells. Unlike sermorelin (which uses residues 1–29 of the 44-residue GHRH sequence) and CJC-1295 (which uses the 1–29 sequence with amino-acid substitutions for DPP-IV resistance), tesamorelin retains the complete 44-amino-acid sequence of native human GHRH(1–44).The key structural modification is the conjugation of trans-3-hexenoic acid to the N-terminus via an amide bond. This fatty acid modification extends plasma half-life without altering the GH secretagogue receptor-binding interface or the core biological activity of the GHRH sequence.
Phase 1 Peptides supplies tesamorelin as a research compound for laboratory use only.
Structural Position in the GHRH Analog Family
Three primary GHRH-axis research peptides span a progression of structural modifications:
| Property | Sermorelin | CJC-1295 (No DAC) | CJC-1295 (DAC) | Tesamorelin |
| GHRH sequence | 1–29 | 1–29 | 1–29 | 1–44 (full) |
| Stability mechanism | Truncation | Ala²→D-Ala, others | Ala²→D-Ala + DAC | N-terminal fatty acid |
| Plasma half-life | ~10–20 min | ~30 min | ~6–8 days | ~26 min |
| Pulsatility profile | Short, mimics native pulse | Intermediate | Extended (non-pulsatile) | Intermediate |
| Clinical research status | Phase 3 completed | Investigational | Investigational | FDA-approved (HIV-LD) |
Tesamorelin's use of the full 44-residue sequence is notable from a receptor-biology standpoint: the additional residues (30–44) contribute to the GHRH receptor (GHRHR) binding interface and are argued in published literature to contribute to more complete receptor activation — though truncated analogs retain primary GH secretagogue activity through the conserved N-terminal domain.
Mechanism: GHRH Receptor Signaling
Tesamorelin binds the GHRH receptor (GHRHR), a class B G-protein-coupled receptor expressed on anterior pituitary somatotrophs. The signaling cascade follows the canonical GHRH pathway:
1. GHRHR activation → Gαs coupling → adenylyl cyclase activation → ↑ cAMP
2. ↑ cAMP → protein kinase A (PKA) activation → phosphorylation of transcription factors (including Pit-1) → GH gene expression
3. ↑ cAMP + ↑ intracellular Ca²⁺ → exocytosis of GH from secretory granules
This pathway operates in parallel with the ghrelin/GHS-R (growth hormone secretagogue receptor) axis. Tesamorelin, like other GHRH analogs, acts through GHRHR and does not directly engage GHS-R. In research models studying GH pulsatility, GHRH analogs are used to probe pituitary somatotroph responsiveness independent of the ghrelin-receptor axis.
Visceral Adipose Tissue Research Context
Tesamorelin has the most extensive published clinical research base of any GHRH analog. It holds FDA approval (as Egrifta™) for the reduction of excess visceral adipose tissue (VAT) in HIV-infected patients with lipodystrophy — a specific syndrome involving abnormal fat redistribution in individuals on certain antiretroviral therapies.
This clinical research base provides published reference endpoints for:
- GH axis dynamics: dose-response relationships between GHRH analog administration and IGF-1 / GH pulsatility parameters in human subjects
- Adipose tissue biology: VAT dynamics, lipolytic pathway activity, and adipokine profiles in response to GHRH receptor stimulation
- Lipid metabolism endpoints: triglyceride kinetics, free fatty acid dynamics, and hepatic lipid metabolism parameters across clinical trial cohorts
In laboratory research contexts, these published datasets serve as reference baselines for experimental models examining GHRH receptor signaling, GH axis modulation, and lipid-metabolism pathway biology.
Note on research posture: Tesamorelin available from Phase 1 Peptides is supplied exclusively for laboratory research use. The FDA approval referenced above applies to a specific pharmaceutical formulation in a defined patient population; it does not apply to research-grade peptide compounds used in laboratory settings.Half-Life and Pulsatility Trade-Off
The trans-3-hexenoic acid modification provides intermediate plasma stability. Native GHRH(1–44) has a plasma half-life under 5 minutes — cleaved rapidly at Ala² by dipeptidyl peptidase IV (DPP-IV) and at other sites by serum proteases. The fatty acid conjugate resists this cleavage sufficiently to extend plasma half-life to approximately 26 minutes without fundamentally altering the pulsatility dynamics.
This positions tesamorelin in the GHRH analog landscape as a compound that:
- Preserves pulsatile GH secretion dynamics (unlike the continuous stimulation profile of long-acting DAC-CJC-1295 conjugates)
- Provides sufficient plasma durability for standard once-daily experimental schedules in published animal and clinical models
- Demonstrates greater structural completeness than truncated 1–29 analogs, maintaining the full receptor-binding interface of native GHRH
For researchers selecting among GHRH analogs, the choice involves trade-offs between pulsatility profile, sequence completeness, and stability mechanism. See the Sermorelin research primer and the CJC-1295 & Ipamorelin research primer for mechanism detail on the other members of this GHRH analog family. For a structured side-by-side comparison of all three analogs, see the GHRH Analog Comparison overview.
Laboratory Handling Notes
Tesamorelin is supplied as a lyophilized powder. Reconstitution follows standard peptide protocols using bacteriostatic water. Store lyophilized at −20 °C; reconstituted solutions at 2–8 °C. Tesamorelin's N-terminal fatty acid conjugate adds lipophilicity relative to unmodified peptides — ensure complete dissolution before use. See the reconstitution guide and peptide storage guide for standard protocols.
Product Availability
Phase 1 Peptides stocks Tesamorelin at 99%+ purity with third-party laboratory documentation.
Q: How does tesamorelin differ from CJC-1295?Both tesamorelin and CJC-1295 are GHRH analogs with extended plasma stability relative to native GHRH. Key differences: (1) sequence length — tesamorelin uses the complete 44-aa GHRH sequence, while CJC-1295 uses the truncated 1–29 fragment; (2) stabilization method — tesamorelin uses an N-terminal fatty acid (trans-3-hexenoic acid) conjugate, while CJC-1295 uses amino-acid substitutions and optionally a Drug Affinity Complex (DAC) albumin-binding moiety; (3) half-life — tesamorelin (~26 min) versus CJC-1295 with DAC (~6–8 days).
Q: Why does tesamorelin have more published clinical data than other GHRH analogs?Tesamorelin reached FDA approval for HIV-associated lipodystrophy, which required extensive Phase 2 and Phase 3 clinical trials. This regulatory pathway produced a larger body of published human clinical data than typically exists for investigational GHRH analogs like sermorelin or CJC-1295. For laboratory researchers, this means more reference endpoints and established assay parameters are available in the peer-reviewed literature.
Q: Does tesamorelin produce continuous GH elevation?No. Unlike DAC-modified CJC-1295, which produces sustained, continuous GH elevation, tesamorelin's intermediate plasma half-life (~26 min) allows GH levels to return toward baseline between administrations. Published protocols observe pulsatile-like GH patterns following tesamorelin administration, which is relevant for research designs where preserving physiological pulsatility dynamics is part of the experimental model.
Q: What is the significance of the full 44-aa GHRH sequence in tesamorelin?Native GHRH(1–44) contains the complete receptor-binding interface for GHRHR. Sermorelin and CJC-1295 use only the N-terminal 1–29 fragment, which retains the primary GH secretagogue activity but lacks the C-terminal residues (30–44) that contribute to the complete binding interface. Published receptor-binding affinity studies have compared these analogs, with some data suggesting the full-length sequence achieves more complete GHRHR occupation. This distinction is relevant for research designs that aim to model the full native GHRH-receptor interaction.
See Also
- GHRH Analog Comparison — side-by-side comparison of all three GHRH analogs
- Peptide Half-Life Reference — compiled pharmacokinetic data across 20+ research peptides
- CJC-1295 + Ipamorelin — GHRH + GHRP synergy protocols
All Phase 1 Peptides products are supplied exclusively for laboratory research and in vitro studies. They are not intended for human or animal consumption, clinical use, or therapeutic application.